On November 5, 2024, Richard Giltner, Director at United Therapeutics Corp (UTHR, Financial), executed a sale of 10,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this transaction, the insider now owns 17,420 shares of the company.
United Therapeutics Corp, a biotechnology firm, focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Over the past year, Richard Giltner has sold a total of 10,000 shares and has not made any purchases. The broader trend within United Therapeutics Corp shows a significant inclination towards insider selling, with 111 insider sales and no insider buys over the same period.
Shares of United Therapeutics Corp were priced at $381.7 on the day of the sale. The company holds a market cap of approximately $17.75 billion. The price-earnings ratio stands at 17.46, which is below the industry median of 26.79, indicating a potentially lower valuation relative to its peers.
The stock's GF Value is estimated at $326.66, suggesting that at a price of $381.7, United Therapeutics Corp is modestly overvalued with a price-to-GF-Value ratio of 1.17.
The GF Value is derived from historical trading multiples like the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and supplemented by analyst estimates of future business performance.
This insider sale could be of interest to investors tracking insider behaviors as an indicator of confidence levels regarding the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
